Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
06/06/2022 18:56
June 6 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD- PROPOSED NEW PRIMARY EFFICACY
ENDPOINTS
MAY INCLUDE RATE OF SUSTAINED CLINICAL RESOLUTION OF SYMPTOMS OF
COVID-19
* REVIVE THERAPEUTICS - FDA AGREED THAT CO MAY UNBLIND
PRE-DOSE-SELECTION DATA FOR FIRST 210 PATIENTS OF STUDY TO
FURTHER SUPPORT NEW PRIMARY ENDPOINT
* REVIVE THERAPEUTICS LTD- DSMB ARE SCHEDULED TO MEET
THEREAFTER
TO EVALUATE INTERIM CLINICAL AND SAFETY DATA
* REVIVE THERAPEUTICS - HAS NOW SUBMITTED DATA ACCESS PLAN
TO FDA
WITH AIM TO UNBLIND PRE-DOSE SELECTION DATA
Source text for Eikon: ID:nGNXVgHmH
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure